Welcome to our dedicated page for Haleon SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haleon plc (HLN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on both the London Stock Exchange and the New York Stock Exchange. Haleon files annual reports on Form 20-F and submits current reports on Form 6-K under the Securities Exchange Act of 1934. These filings cover topics such as trading statements, total voting rights and capital, board and committee changes, and transactions by persons discharging managerial responsibilities (PDMRs).
Recent 6-K filings include announcements on Haleon’s Q3 trading statement, regular updates on total voting rights and capital, and detailed notifications of share transactions under the company’s share reward plans by senior managers. Other filings describe governance developments, such as the appointment of a new Chair, changes to the Senior Independent Director role and committee memberships, and the evolution of Haleon’s operating model, including the creation of six Operating Units and new executive roles like Chief Growth Officer and Chief Transformation Officer.
Many filings contain an "About Haleon" section that reiterates the company’s profile as a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other, along with examples of long-standing brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren.
On this page, investors can review Haleon’s SEC submissions as they are made available from EDGAR, while AI-powered tools on the platform can help summarise key points, highlight changes over time and surface information on areas such as capital structure, insider share dealings disclosed as PDMR transactions, and updates to the company’s governance and operating model.
Haleon plc (HLN) published a TR-1 notification reporting a significant shareholding held by Wellington Management group entities. The notification shows 418,575,113 direct voting rights, representing 4.69% of the company's voting rights. In addition, financial instruments reported in the notice amount to 26,175,050 voting rights (sub‑totals listed under 8.B1 and 8.B2), producing a total reported interest of 4.98% when instruments are included. The filing lists multiple Wellington controlled undertakings and indicates the chains of ownership through Wellington Management Group LLP and its affiliates that manage assets for funds and managed accounts. The disclosure is provided under the FCA/DTR rules as required for major holdings.
Haleon plc announced the purchase of 5,150,000 ordinary shares of £0.01 each on 23 September 2025 as part of the second tranche of its share buyback programme. The company intends to hold the purchased shares as treasury shares.
After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 33,337,545 are treasury shares, leaving 8,919,016,103 ordinary shares with voting rights. The announcement includes a link to a full breakdown of individual trades and clarifies it is not an offer for securities.
Haleon plc announced the purchase of 5,150,000 ordinary shares under the second tranche of its share buyback programme. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 28,187,545 are held as treasury shares, leaving 8,924,166,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided London Stock Exchange link and on the Company website.
Haleon plc announced the purchase of 4,150,000 ordinary shares of £0.01 each on 19 September 2025 under the second tranche of its share buyback programme announced 31 July 2025. The shares were purchased on the London Stock Exchange and CBOE (UK)/CXE across the session; a full breakdown of individual trades is provided via the Company link. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 23,037,545 are treasury shares, leaving 8,929,316,103 voting shares.
Haleon plc reports it purchased 4,314,000 ordinary shares of £0.01 each under the second tranche of its buyback programme announced 31 July 2025. The company intends to hold the purchased shares as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares, of which 18,887,545 are treasury shares, leaving 8,933,466,103 ordinary shares with voting rights. Shareholders may use the voting-rights figure to determine notification obligations under the FCA Disclosure Guidance and Transparency Rules. A full breakdown of individual trades is available via the provided RNS link and on the company website.
Haleon plc completed a tranche of its share buyback programme, acquiring 5,214,540 ordinary shares (â£0.01 each) on 17 September 2025. The company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 14,573,545 are held in treasury, leaving 8,937,780,103 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company's investor website.
Haleon plc announced the purchase of 5,357,044 ordinary shares of £0.01 each under the second tranche of its buyback programme. The company will hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares, of which 9,359,005 are held in treasury, leaving 8,942,994,643 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the company's investor website. The announcement notes this does not constitute an offer for securities.
Haleon plc purchased 1,500,000 ordinary shares under the second tranche of its buyback programme announced 31 July 2025. The shares were bought on 15 September 2025 on the London Stock Exchange/CBOE (UK)/CXE and the company intends to hold the purchased shares as treasury shares.
After settlement the company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 4,001,961 are held as treasury shares, leaving 8,948,351,687 ordinary shares with voting rights. The announcement points investors to a full trade breakdown at the provided link and to Haleon's investor website for details.
Haleon plc announced on 15 September 2025 that it purchased 997,991 ordinary shares of each under the second tranche of its share buyback programme announced 31 July 2025. Of the purchased shares, 23,788 will be cancelled and 974,203 will be held as treasury shares. After settlement the company's registered share capital is 8,952,353,648 ordinary shares of each, with 2,501,961 held as treasury shares and 8,949,851,687 shares with voting rights.
The announcement notes a full trade breakdown is available via the provided RNS link and on the company's investor website.
FAQ
What is the current stock price of Haleon (HLN)?
What is the market cap of Haleon (HLN)?
